Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other ch
Hard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has agreed a deal to ramp up manufacturing – and claim the first
Hopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results from the first large-scale trial of Sanofi
Regeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch biotech and cueing up a third trial of their immuno-oncology combina
Regeneron has said it has begun clinical trials of its antibody cocktail therapy for COVID-19, as pharma companies continue their search for treatments as the pandemic continues to cause ha